MGX

Metagenomi, Inc. Common Stock (MGX) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Financial Risk

Balance sheet liquidity is strong with a current ratio of 4.50 and cash ratio of 1.41, while debt remains modest at 0.34x debt-to-equity.

Profitability remains deeply negative, with TTM operating margin at -7.42% and net margin at -6.89%, indicating ongoing earnings pressure.

Cash generation is weak on a TTM basis, with free cash flow negative and free cash flow yield at -1.96%.

Operational Risk

Gross margin is still healthy at 74.29%, but it is not translating into operating profit because SG&A and R&D remain heavy relative to revenue.

Working capital efficiency is mixed: receivables turnover is reasonable at 15.07x, but payables days are very high at 272.47 and the cash conversion cycle is negative.

Asset efficiency remains poor, with asset turnover at 0.08x and return on capital metrics still negative.

Valuation Risk

The stock screens as inexpensive on asset-based measures, with price-to-book at 0.39x and price-to-sales at 3.22x.

However, valuation is hard to anchor because earnings and cash flow remain negative, making earnings-based multiples and yields less meaningful.

Net debt is low relative to EBITDA, so leverage is not the main valuation concern.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Metagenomi, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →